Studies suggest that Fragment 176-191, which is a lipolytic fraction of the larger hGH protein, might provide properties such as the following:
- Redistribution and dissolution of fat cells
- Cell regeneration in cartilage tissues
In this guide, we explain this well-known molecule's possible applications within research studies, and its potential mechanisms of action. In conclusion, we will discuss the most reliable provider of research peptides for weight regulation research, including Frag 176-191 and other amino acids.
Table of Contents
Fragment 176-191 Peptide: What is it?
In growth hormone (hGH), “Fragment 176-191” refers to the peptide fragment composed of amino acids 176 to 191 of hGH. This portion of growth hormone, called its C-terminus, is thought to be the primary contributor to the fat-reducing potential of hGH.
Several investigations have indicated that Fragment 176-191 presentation may reduce fat mass and total weight, as suggested in animal research models. The stability of the peptide is believed to be improved by the addition of tyrosine and the N-terminus, which is an extra modification performed on the peptide. As a result, it is also known as AOD-9604. Another name for it is Tyr-hGH 177-191.
The potential of intact growth hormone in fat cell reduction and metabolic function have been the subject of much study. However, because of the significant adverse effects that are associated with long-term exposure with growth hormone supplementation (hGH), such as glucose intolerance and hypertension, research that evalues intact hGH for an extended period on animal models is not feasible. According to the available research, Fragment 176-191 may have the potential to induce several physiolocial impacts, which we will investigate in further detail in the next section.
Fragment 176-191 Peptide Research
According to the findings of scientific investigations, several potential actions appear to be associated with exposure to hGH Fragment 176–191. We will summarize the most important prospective properties of this peptide in this part, taking into account the data that is already accessible.
Fragment 176-191 Peptide and hGH
Considering all of the material that has been published, it seems that hGH Fragment 176-191 may have a favorable profile when tested on laboratory animals. Research indicates it may not be connected with the side effects of growth hormone (hGH), such as insulin resistance. It looks to be a better option for researchers who wish to examine the fat-reducing characteristics of growth hormone (hGH) without employing full amounts of hGH and exposing animal models to its associated hazards.
Regarding mobilizing lipids in the organism, one of the primary properties of growth hormone (hGH), the carboxy terminus of hGH, also known as hGH 177-191, seems to have a significant influence. Edema, hypertension, acromegaly, diabetes, and glucose intolerance are some of the dangers that are connected with growth hormone (hGH). However, no data suggests that Fragment 176-191 may be related to any of these concerns.
Fragment 176-191 Peptide and Lipid Mobilization
The possible effect that hGH Fragment 176-191 has on the mobilization of lipids is the second possible property of this compound. Research conducted on intact growth hormones has indicated that it may hinder lipoprotein lipase's function in adipose tissue and may encourage lipolysis in adipocytes. Studies conducted by other researchers have purported that there may be a practical effect on fat mass cells, fat mass, and total fat cell distribution. Research employing hGH Fragment 176-191 has implied that it may induce a sustained rise in plasma insulin levels and cause a temporary increase in blood glucose levels.
Fragment 176-191 was hypothesized to have an increase in thermogenic activity in the skeletal muscle of obese mice and beta(3)-AR knock-out mice in a research conducted in 2001. In light of this, it seems that Fragment 176-191's prospective relevance in research might include subject areas of obesity, prediabetes, and type 2 diabetes in research models.
Fragment 176-191 Peptide and Cartilage Regeneration
In a research that was conducted in 2013, it was speculated that when white rabbits who were suffering from osteoarthritis (OA) were given concentrations of Fragment 176-191 in combination with hydrochloric acid (HA), they exhibited a growth of cartilage that appeared much higher than when they were given HA alone.
The research authors theorized that since Fragment 176-191 may not induce the creation of IGF-1, it “may be safer than … recombinant GH for the long-term management of OA.” This is even though these findings have not yet been duplicated.
Fragment 176-191 can be purchased if you are a researcher interested in further studying the potential of this peptide. Please note that none of the substances mentioned in this article have been approved for human consumption and should, therefore, not be used by unlicensed individuals.
References
[i] Stier, Heike et al. “Safety And Tolerability Of The Hexadecapeptide AOD9604 In Humans”. Jofem.Org, 2021, https://www.jofem.org/index.php/jofem/article/view/1 57.
[ii] Ho KK, O'Sullivan AJ, Hoffman DM. Metabolic actions of growth hormone in man. Endocr J. 1996 Oct;43 Suppl:S57-63. doi: 10.1507/endocrj.43.suppl_s57. PMID: 9076343.
[iii] Vijayakumar A, Novosyadlyy R, Wu Y, Yakar S, LeRoith D. Biological effects of growth hormone on carbohydrate and lipid metabolism. Growth Horm IGF Res. 2010;20(1):1-
[iv] Gravhølt CH, Schmitz O, Simonsen L, Bülow J, Christiansen JS, Møller N. Effects of a physiological GH pulse on interstitial glycerol in abdominal and femoral adipose tissue. Am J Physiol. 1999 Nov;277(5):E848-54. doi: 10.1152/ajpendo.1999.277.5.E848. PMID: 10567011.
[v] Takahashi S, Satozawa N. The 20-kD human growth hormone reduces body fat by increasing lipolysis and decreasing lipoprotein lipase activity. Horm Res. 2002;58(4):157-64. doi: 10.1159/000065488. PMID: 12324712.
[vi] Rosenbaum M, Gertner JM, Leibel RL. Effects of systemic growth hormone (GH) administration on regional adipose tissue distribution and metabolism in GH-deficient children. J Clin Endocrinol Metab. 1989 Dec;69(6):1274-81. doi: 10.1210/jcem-69-6-1274. PMID: 2685009.
